{"title":"The role of primary RPLND in clinical stage IIA/B testicular germ cell tumor: a narrative review.","authors":"Parth Thakker, Connor Drake, Timothy Masterson, Clint Cary","doi":"10.1007/s00120-025-02648-9","DOIUrl":null,"url":null,"abstract":"<p><p>Retroperitoneal lymph node dissection (RPLND) plays a critical role in the multidisciplinary management of advanced testicular cancer. Cisplatin-based chemotherapy regimens have been the cornerstone of treatment for these patients. Long-term toxicity and secondary malignancy in patients receiving cisplatin, along with surgical advancements, have encouraged providers to revisit the role of primary RPLND for patients with stage IIA/B germ cell tumor. Nerve-sparing primary RPLND offers durable oncologic outcomes without the long-term comorbidities associated with chemotherapy. The focus of this review is to summarize the published data on primary RPLND for stage IIA/B germ cell tumors, to identify the ideal patient population for this treatment modality, and to explore the future of surgical advancements.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02648-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Retroperitoneal lymph node dissection (RPLND) plays a critical role in the multidisciplinary management of advanced testicular cancer. Cisplatin-based chemotherapy regimens have been the cornerstone of treatment for these patients. Long-term toxicity and secondary malignancy in patients receiving cisplatin, along with surgical advancements, have encouraged providers to revisit the role of primary RPLND for patients with stage IIA/B germ cell tumor. Nerve-sparing primary RPLND offers durable oncologic outcomes without the long-term comorbidities associated with chemotherapy. The focus of this review is to summarize the published data on primary RPLND for stage IIA/B germ cell tumors, to identify the ideal patient population for this treatment modality, and to explore the future of surgical advancements.